报价延迟最少15分钟:2025/09/04 11:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.3 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-30.78/-7.41
|
|
企业价值
8.56M
|
| 资产负债 |
|
每股账面净值
0.16
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/04 11:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulationof cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed. |
